TLR2 and non-Hodgkin lymphoma: For example, a clinical trial treating 11 patients with non-Hodgkin’s lymphoma showed that tandem of a Toll-like receptor 2 (TLR2) TIR structural domain in a CD28-based CAR structure targeting CD19 resulted in severe CRS in 2 patients (18%) and severe ICANS in 1 patient (9%) (NCT04049513) (103).